Former i3 CEO Bilawsky tapped to lead Precision Health Economics
Health economics partnership Precision Health Economics (PHE) has named Glenn Bilawsky as its CEO. The healthcare consultancy, known for its exceptional, highly decorated and connected team has experienced rapid growth and is looking to Bilawsky to underpin its success with a strategy and business platform that will ensure stability while accelerating expansion of the business.
Bilawsky served as CEO of the i3 division of UnitedHealth Group for more than eight years. He brings more than a quarter century of pharmaceutical and contract research experience and has been instrumental in helping several organizations achieve global leadership positions.
"We have a slate of brilliant researchers and analysts who are in demand by our clients throughout the healthcare industry and in the highest levels of government,” said Darius Lakdawalla, co-founder of PHE. “We need a proven leader with the business acumen to refine our strategy while creating and managing a platform for growth. Glenn is that person."
PHE was formed in 2005 by Tomas Philipson, Dana Goldman and Lakdawalla, all renowned health economists from elite universities. Their goal was to use sophisticated, data-driven analysis tailored to each client's strategic needs, and to improve public policy through insightful, issue-driven research. Today the firm has three offices across the country and a network of affiliated academic economists and clinicians from the world's leading universities. Bilawsky plans to expand the national footprint, then move into Europe and Asia.
"This is a rare opportunity to step in at this stage to help shape PHE's growth and provide the strategic and operational platform to fuel its expansion," said Bilawsky. "The cost of healthcare is a global concern. There is a rapidly growing need for information and guidance from a trusted source for all constituents: payers; providers; and manufacturers of pharma, biotechnology, medical device and diagnostic products. I have the good fortune to build on PHE's many assets, which include its preeminent expertise and brand reputation in both the total healthcare and government markets. The PHE team and its network have no peer in the industry."